ACE inhibitory czy sartany po zawale serca – dane z rejestru Korea Acute Myocardial Infarction Registry

Choi IS i wsp. Angiotensin-converting enzyme inhibitors provide better long-term survival benefits to patients with AMI than angiotensin II receptor blockers after survival hospital discharge. J Cardiovasc Pharmacol Ther. 2018

In the present study, by analyzing a large AMI registry data, we showed that ACEI therapy in patients with AMI provided better long-term survival benefits than ARB therapy.

Journal of Cardiovascular Pharmacology and Therapeutics